Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 2/3 1Phase 1 1

Status

Not yet recruiting 2Suspended 1Active not recruiting 1

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1

Conditions

Multiple Myeloma 2Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Plasma Cell 1

Interventions

Specimen Handling 195Magnetic Resonance Spectroscopy 148Biopsy 117pembrolizumab 91Carboplatin 85Cisplatin 77Nivolumab 71Cyclophosphamide 69Paclitaxel 64Gemcitabine 52Radiotherapy 48Bevacizumab 44durvalumab 41Dexamethasone 37Fluorouracil 35Doxorubicin 35venetoclax 34Pemetrexed 33Capecitabine 33olaparib 32Rituximab 31Oxaliplatin 31Injections 31atezolizumab 30Etoposide 29fludarabine 28Radiation 28Prednisone 28Lenalidomide 27Docetaxel 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Hyaluronoglucosaminidase × 30 days × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

NCT07605416 2026-05-26

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
74 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT06169215 2026-05-13

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled
Plasma cell

Multiple Myeloma

NCT06948084 2026-05-13

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
80 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡